CLSI C56 A : 1ED 2012

Abstract
Committee Membership
Foreword
1 Scope
2 Introduction
3 Standard Precautions
4 Terminology
5 Scientific Basis of Hemolysis, Icterus, and
   Lipemia/Turbidity Indices
6 Use of Hemolysis, Icterus, and
   Lipemia/Turbidity Indices
7 Determination of Hemolysis, Icterus, and
   Lipemia/Turbidity Indices
8 Estimation of Hemolysis, Icterus,
   Lipemia/Turbidity Interference Effects
9 Establishing Hemolysis, Icterus, and
   Lipemia/Turbidity Alert Indices and Gray Zones
10 Reporting Hemolysis, Icterus, and
   Lipemia/Turbidity Interference Claims by Manufacturers
   in Product Labeling
11 Potential Process Outcomes of Interferent
   Measurements/Estimates
12 Suggested Annotation Terminology for Result
   Reporting
13 Verification and Quality Control of Hemolysis,
   Icterus, and Lipemia/Turbidity Indices and Alert
   Indices in the Clinical Laboratory
References
Appendix A - Path of Workflow for Hemolysis, Icterus,
             and Lipemia/Turbidity Measurements in the
             Clinical Laboratory
Appendix B - Worked Example of Establishing
             Hemolysis, Icterus, and Lipemia/Turbidity
             Indices
The Quality Management System Approach
Related CLSI Reference Materials

Specifies background information on mechanisms of hemolysis, icterus, lipemia/turbidity (HIL) interference; intended usefulness of HIL indices; establishment of HIL alert indices; availability of automated HIL detection systems; and interpretation, strengths, limitations, and verification of HIL indices in the clinical laboratory.

Hemolysis, icterus, and lipemia/turbidity (HIL) indices are often measured on serum and plasma, to assess sample quality.